This is a preprint.
Ubiquitin-Proteasome System Dysregulation in Alzheimer's Disease Impacts Protein Abundance
- PMID: 40501941
- PMCID: PMC12154775
- DOI: 10.1101/2025.05.29.656728
Ubiquitin-Proteasome System Dysregulation in Alzheimer's Disease Impacts Protein Abundance
Abstract
Alzheimer's disease (AD) is a relentlessly progressive, fatal neurodegenerative disorder associated with widespread aberrant proteomic changes. The full extent of protein dysfunctions in AD and their impact on cellular physiology remains unknown. Here, we used plexDIA, an approach that parallelizes the acquisition of samples and peptides, to characterize proteomic changes in AD. Using human dorsolateral prefrontal cortex tissue, we identified 281 differentially abundant proteins in AD. By systematically analyzing cellular compartment-specific shifts in protein abundance, we identified an AD-specific decrease in levels of the 20S proteasome, the catalytic core of the cell's primary protein degradation pathway. This alteration was accompanied by widespread decreases in proteasome subunit stoichiometries. Many proteasome substrate proteins were negatively correlated with 20S levels and increased in AD, suggesting that reduced 20S levels leads to abnormal protein accumulation. By analyzing proteins increased in AD, we identify key properties of such proteins. Namely, they have highly specific subcellular localizations and fast degradation rates, they contain signal sequences that allow them to be targeted for proteasomal degradation, and they are targeted by quality control pathways that recognize mislocalized proteins. Furthermore, we identify coherent sets of ubiquitin system enzymes, proteins that target substrates for proteasomal degradation, whose levels robustly discriminate AD from non-AD samples. One subset exhibited consistent increases in AD, while another exhibited consistent decreases, revealing complex alterations to the ubiquitin system in AD. Taken together, our results suggest that decreased ubiquitin-proteasome system capacity and impaired clearance of short-lived and mislocalized proteins contribute substantially to proteopathic burden in AD.
Conflict of interest statement
Competing Interest N.S. is a founding director and CEO of Parallel Squared Technology Institute, which is a nonprofit research institute. The authors declare no other competing interest.
Figures






Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Factors that influence the provision of intrapartum and postnatal care by skilled birth attendants in low- and middle-income countries: a qualitative evidence synthesis.Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD011558. doi: 10.1002/14651858.CD011558.pub2. Cochrane Database Syst Rev. 2017. PMID: 29148566 Free PMC article.
-
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079. Health Technol Assess. 2024. PMID: 39046101 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. doi: 10.3310/hta10010. Health Technol Assess. 2006. PMID: 16409879
References
-
- Kumfor Fiona, Halliday Glenda M, and Piguet Olivier. Clinical aspects of alzheimer’s disease. Advances in neurobiology, 15:31–53, 2017. - PubMed
-
- Jarvik L Alzheimer A and Greenson H. About a peculiar disease of the cerebral cortex. by alois alzheimer, 1907 (translated by l. jarvik and h. greenson). Alzheimer Dis Assoc Disord, 1:3–8, 1987. - PubMed
-
- Mirra S S. The cerad neuropathology protocol and consensus recommendations for the postmortem diagnosis of alzheimer’s disease: a commentary. Neurobiology of aging, 18:S91–4, 1997. - PubMed
-
- Khachaturian Z S. Diagnosis of alzheimer’s disease. Archives of neurology, 42:1097–105, 1985. - PubMed
-
- Braak H. and Braak E.. Neuropathological stageing of alzheimer-related changes. Acta neuropathologica, 82:239–59, 1991. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources